Zydus receives USFDA’s final approval for Gabapentin Tablets, 300 mg and 600 mg

Gabapentin is indicated for the management of Postherpetic Neuraligia

Laurus Labs inks JV agreement with KRKA, Slovenia

The registered capital of the newly founded company is € 50 million

Laurus Labs posts Q3 FY24 consolidated PAT at Rs. 23.14 Cr

Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023

Aster DM Healthcare gets shareholders nod to separate the GCC business

The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years

Lupin receives tentative USFDA approval for Rivaroxaban Tablets USP

Zydus and Synthon inks licensing and supply agreement for Palbociclib Tablets for US market

Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets

Lupin receives USFDA’s approval for Febuxostat Tablets

Febuxostat Tablets (RLD Uloric) had estimated annual sales of US$ 27 million in the U.S. (IQVIA MAT November 2023)

Zydus receives USFDA’s approvals for Pimavanserin Capsules, 34 mg and Pimavanserin Tablets,10 mg

Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis

Venus Remedies eceives GMP certification from Libya

The certification underscores Venus Remedies Limited's adherence to stringent quality control measures

NATCO invests US$ 2 million in Cellogen Therapeutics

Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy